Solving Life-Threatening Problems in Oncology

Cancer Statistics and Economic Burden

• Currently, 198 new cancer diagnoses occur in the United States every hour.
• 70 people die of cancer during the duration of this panel discussion.
• Approximately 600,000 Americans die from cancer annually, a figure equivalent to the total population of Boston, Massachusetts.
• Globally, 7 million people die from cancer annually, with 4 million of those being preventable premature deaths.
• Cancer patients are 2.1 times more likely to file for bankruptcy within one year of diagnosis compared to the general population.
• U.S. National Institutes of Health (NIH) funding for cancer research has grown exponentially, rising from $300 million in 1961 to $40 billion annually today.
• The cost of treating cancer places a significant financial burden on families, often forcing patients to mortgage homes for life-saving drugs.

Panelist Profiles and Expertise

• Howard Sewell: Chief Science Officer at the Prostate Cancer Foundation (PCF) with 20 years of experience at the Milken Institute Global Conference.
• Rajiv Kaul: Head of Fidelity Select Biotech portfolio for 20 years, managing one of the world's largest biotechnology investment funds.
• Dr. Freda Lewis-Hall: Chief Medical Officer at Pfizer, with a career focus on healthcare disparities and precision medicine implementation.
• David Reese: Head of Translational and Early Development at Amgen, specializing in new cancer therapies.
• Mark Simon: Consultant at Tarea Partners and former executive at Roberts and Stevens/Citibank, with decades of experience funding and evaluating biotech startups.

Key Trends in Biotechnology and Innovation

• Scientific Advancement: The field is experiencing an explosion in precision oncology, immunotherapy, gene reprogramming, and RNA engineering, driven by decreasing costs in biological interrogation tools.
• Investment Reality: While the scientific "hope factor" is high, investors face high failure rates; most companies will not succeed, and success requires distinguishing between scientific excitement and executable business data.
• Clinical Trial Enrollment: Only 5% of cancer patients enroll in clinical trials, creating a bottleneck for advancing cures.
• Diagnostic Revolution: Advances in cell-free DNA, circulating tumor DNA, and next-generation sequencing have made it possible to target treatments based on genetic mutations rather than tumor location (e.g., Keytruda approval for MSI-high patients across all tumor types).
• Failure and Correction: High-profile failures, such as the Juno Therapeutics clinical hold due to fatal side effects in 2016, can be corrected through rapid regimen changes and re-engineering, leading to massive acquisitions (e.g., Juno acquired by Celgene for $9 billion).
• Investment Criteria: Mark Simon identifies "intellectual capital" (team experience, academic KOLs) and "humility" (acknowledging unknowns) as the primary predictors of success for early-stage companies.
• Genentech Success Story: Genentech's valuation grew from $5 billion in 2000 (with two drugs) to a $100 billion acquisition by Roche in 2009, driven by Rituxan and Herceptin.

Barriers to Access and Equity

• The "Flintstones" Problem: Advanced "Star Wars" level medicines are being delivered through outdated, inefficient healthcare systems that hinder widespread adoption.
• Clinical Trial Rigidity: Protocols often exclude patients with comorbidities or fail to account for patient desires (e.g., extending an 8-week PTSD trial when patients wish to continue), leading to lost data and patients.
• Disparities in Care: African-American men are twice as likely to die from prostate cancer compared to other groups, even after adjusting for socioeconomic factors.
• Accessibility Gaps: Precision diagnostics are largely confined to academic centers (e.g., Dana-Farber, MD Anderson); only ~10% of community oncology patients receive comprehensive sequencing compared to 90% in top-tier centers.
• Bureaucratic Barriers: Complex FDA requirements (e.g., REMS programs with 40 pages of paperwork) can render life-saving drugs inaccessible to inner-city hospitals lacking administrative staff.
• Process Failures: Logistics issues, such as inadequate biopsy sample sizes and shipping delays (e.g., biopsies collected on Thursday arriving at labs on Tuesday), significantly delay diagnostic results.
• All-Comer Trials: New paradigms like the "Stampede" trial in the UK utilize adaptive designs to enroll all patients, automatically expanding successful arms and euthanizing ineffective ones without turning anyone away.

Patient Priorities and Lifestyle Factors

• Patient-Defined Endpoints: The McMillan study revealed that patients prioritize understanding "how they will live with cancer" and "prevention strategies" over longevity statistics; "quality of life" and relationship maintenance are emerging as critical research endpoints.
• Prevention Efficacy: Clinical trials have debunked the efficacy of dietary supplements (selenium, vitamin E, D, calcium) for cancer prevention; lifestyle factors remain unproven by supplements but supported by broad epidemiology.
• Confirmed Preventive Measures: The single most effective public health intervention is avoiding tobacco; moderate alcohol consumption, regular exercise, and adherence to screening (colonoscopies) are the only evidence-based prevention strategies.
• Social Determinants: Harvard longitudinal studies identify "meaningful relationships" as the strongest correlation with longevity and health, surpassing traditional medical interventions like statins.
• Genetic Influence: Telomere length preservation in leukocytes shows a high correlation with longevity, suggesting stress management is as critical as diet and exercise.

Regulatory and Systemic Recommendations

• FDA Role: Speakers advocate for an FDA that understands the urgency of biological science, comparing the current drug approval process to an unrealistic requirement for smartphone software updates.
• Data Integration: The ecosystem must move toward making every patient interaction a research interaction, utilizing big data to aggregate inconsistent medical records for meaningful queryability.
• Democratization: A primary goal is to shorten the "tail" of the learning curve to ensure community oncologists can access and utilize advanced diagnostics and precision therapies.
• Patient Partnership: Pharmaceutical companies must integrate patients into the design of trials and protocols to ensure relevance and improve enrollment rates.